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Preparative regimens
BEAM D-5 D-4 D-3 D-2 D-1
Etoposido 200-300 mgs/m2/day X X X X
BiCNU 300 mgs/m2/day X
Citarabine 300 mgs/m2/day X X X
Melfalan 140 mgs/m2/day X
CBV
Cyclosphaphamide 2.000 mgs/m2/day X X X
BiCNU 300 mgs/m2/day X
Etoposide 300 mgs/m2/day X X X
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compare responses and toxicities.
Results: The median age of the patients was 58 yrs (range:
39-72) in Group A and 58 yrs (range: 49-68) in Group B.
Group A had more female pts (56% vs 25%) and a decreased
baseline renal function (median creatinine clearance 76 vs
108 ml/min) compared to Group B. There was no signiﬁcant
difference in disease status pre-2nd ASCT between the 2
groups. Salvage therapywas given to 12 pts in group A and 16
pts in group B. The median time between 2 ASCTs were 29
(range: 3-67) months in group A vs 35.5 (range: 18-58)
months in group B. All patients received stem cells which
were collected and cryopreserved prior to the 1stASCT. At day
+100, seven patients from Group B had CR compared to 2
from group A (p¼.11) (Table 1). Patients who received BEAM
had higher incidence of febrile neutropenia (16 vs 10 pts) and
longer hospitalization (23 vs 15 days, p <.0001). Other
toxicities were not signiﬁcantly different between these
groups.
Conclusion: BEAM seems to be a viable and tolerable con-
ditioning regimen for 2ndASCT in MM pts. Further analyses
including PFS and OS are planned to better deﬁne the two
groups.143
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Small series have shown that it is possible perform autolo-
gous hematopoietic transplant in lymphoma patient without
cryopreservation. In most of them, CBV like or BEAM liker-
egimen were used, but with important modiﬁcations of the
intensity of dose delivered, or using different drugs . We
present our experience in a large group of lymphoma pa-
tients using non-cryopreserved stem cells after administra-
tion of BEAM or CBVwithout alteration of the total amount of
chemotherapy of these regimens.
The mobilization was done with ﬁlgrastin 5 mg/kg/BID for
ﬁve to six days, after that, one or two leukopheresis of 3 to 5
blood volume was done; the cells were stored at 4oC, 6 days
for ﬁrst leukopheresis, and 5 for the second one. The pre-
parative regimen began in the evening of the last pheresis,
this was the day e 5. All patients received ﬁlgrastim or
pegﬁlgrastim after the transplant82 ptes in whom were
collected at least 1.0 x 10(6) CD 34/kg (X: 2.5) were trans-
planted; 49 were men, median age was 36 Y (11-65), 42 had
Hodgkin disease and 40 had lymphoma, the totality of them
were in CR2 or beyond. 65 received BEAM and 17 CBV. The
median viability of the cells after 6 days of refrigeration
(trypan blue exclusion) was 82% (range 66-90). All patients
had fast and complete neutrophil engraftment; median time
to achieve 500/ul or more was 12 days (9-23), 79 were
evaluable for thrombopoiesis, 78 of them had a self- sus-
tained platelets count of 20.000 or more at a median of 17
days (range 9-50). There has not been secondary engraft-
ment failure.
The tolerance and efﬁcacy of the BEAM and CBV adminis-
tered in 5 days was good; the transplant related mortality
was 3.6% and the Kaplan Meir estimate for OS at 36 months
was 65% and 58% for patients with Hodgkin and lymphoma
respectively.We conclude; the use of non-cryopreserved stem cell for
supporting autologous transplant after a BEAM or CBV con-
ditioning is feasible, safe, and produce a fast, complete and
sustained hematopoiesis. This simple procedure is a good
alternative for saving costs and it can expand the number
of lymphoma patients who would receive the beneﬁt of
tranplant.144
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Background: Standard initial therapy for a minority of
patients with systemic AL amyloidosis is risk-adapted
melphalan and stem cell transplant (SCT) with SC mobiliza-
tion often accomplished with high dose G-CSF (16mg/kg/d).
Based on the phase III experience in MM, we investigated the
combination of G-CSF and Plerixafor for stem cell mobiliza-
tion in AL. We report an update of our experience with this
mobilization approach.
Methods: Patients were diagnosed by standard criteria with
tissue biopsies showing amyloidosis. They were mobilized
and collected between 4/16/12 and 9/11/13 with G-CSF 10mg/
kg/d subcutaneously (SC) for 5 days (and continued through
collection) and Plerixafor, adjusted for renal function, start-
ing on day 4 until collection was completed.
Results: We report on 12 patients whose median age at
mobilization was 58 yrs (range 46-72), 58% of whom were
men. Median number of organs involved was 2 (range 1-4),
most frequently the kidneys (n¼9) and the heart (n¼8).
Median time from diagnosis to mobilization was 7.5 mths
(range 2-123). 9 patients had prior bortezomib-based ther-
apy with a median of 3 cycles (range 0-6). One had received a
SCT 10 years prior and relapsed, and one was 1 yr s/p
orthotopic heart transplant. 5 patients had a creatinine of 
1.5 mg/dL including 2 on hemodialysis. The target CD34+ cell
dose was 10 x 106 CD34/kg for all but one patient due to the
history of prior SCT. The median number of collections was 2
(range 2-3). On day one, a median of 3.6 x106 CD34/kg (0.4-
13.8x106) was collected and on day two, 6.4 x106 (2.7-
19x106). The median total CD34+ cells collected per kg was
13.8x106 (5-18x106). No signiﬁcant toxicities were observed
with Plerixafor. 2 patients had grade 1 bleeding from the
catheter site during apheresis and one had dyspnea with
suspected ﬂuid overload which responded to furosemide.
All patients went on to receive high dose chemotherapy
with melphalan followed by autologous SCT. The median
stem cell dose infused was 7.7x 106 CD34/kg and median
days to ANC > 500 was 11 (10-22), to platelets > 20K
untransfused was 22 (15-44) and to lymphocytes > 500/ml
was 14.5 (11-25). One patient who had VOD and persistent
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on day +31 due with subsequent normalization of his CBC.
Conclusions: Mobilization with G-CSF and Plerixafor was
well tolerated in AL patients with multiple organs involved.
Limited leukaphereses were needed to achieve or exceed the
target CD34+ cell dose. In the era of more effective initial
therapies, an era in which many AL patients are living longer
with moderate to severe organ damage and receiving mul-
tiple lines of therapy including SCT, this approach allows not
only the collection of sufﬁcient CD34+ cells for optimal im-
mediate stem cell dosing, but also the cryopreservation of
aliquots for future transplants should they become necessary
and for novel cell-based therapies should they become
available.145
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In spite of intensive multimodal therapy including HSCT, it is
difﬁcult to assess remission in NB. We have previously
demonstrated thatWT1is a surrogate marker of proliferation
in leukemia. To assess the status of NB cell proliferation post
HSCT, WT1 gene expression was evaluated. 42 random bone
marrow (BM) samples (from 34 patients) were obtained, at
diagnosis (n¼24) and post HSCT (n¼18; 13 in remission and
5 in clinical relapse). Quantitative RT-PCR was used for the
evaluation of the level of gene expression as positive (> 1 x
100 ng/ml), weakly positive (9.9 x 10-1 to 6.5 x 10-1 ng/ml) and
negative (< 6.5 x 10-1 ng/ml). Results were extrapolated from
a ten fold serial dilution standard curve using a NB cell line
(NGP). The levels of WT1 gene expression in NGP were
arbitrarily deﬁned as 1.0. The integrity of RNAwas conﬁrmed
by ampliﬁcation of the housekeeping gene GAPDH. At diag-
nosis 83% (18/24 positive, 2/24 weakly positive) (95.9 + 74.2
(0.890- 1500) ng/ml) patients expressed theWT1 gene, where
17% (4/24) (0.199 + 0.0946 (0.007- 0.440) ng/ml) were nega-
tive. Post HSCT in remission 92% (12/13) were negative
(0.0822 + 0.0192 (0.0026-0.200) ng/ml) in comparison to the
time of clinical relapse where 60% (3/5) (1.57 + 0.418 (1.10 e
2.40) ng/ml) were positive for WT1 gene expression. A com-
parison t-test was performed between the initial gene
expression at diagnosis to remission and only positive WT1
gene expression at diagnosis to clinical relapse. Signiﬁcant
difference (p<.0002) was found when comparing WT1
transcription at diagnosis to remission, whereas insigniﬁ-
cance (p<.5) was found when comparing positive WT1
expression at diagnosis to clinical relapse. This signiﬁes that
the WT1 gene is indicative of cellular proliferation further
illustrating the status of BM involvement in NB patients post
HSCT.146
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AuHCT is commonly an inpatient procedure. Due to im-
provements in supportive care, many centers now perform
AuHCT on an outpatient basis. We compared the outcome of
95 outpatients (OP) and 135 inpatients (IP) that underwent a
ﬁrst AuHCT from July 2009 to December 2012 formyeloma or
lymphoma usingmelphalan or BEAM conditioning at a single
center. Selection for OP AutoHCT was based on expected
compliance, proximity to the cancer center for daily visits,
24-hour caregiver support, and favorable performance status
and co-morbidity proﬁle. Both groups received the same
chemotherapy or supportive care, except that the OP group
received more aggressive prophylactic antibiotic support
during neutropenia and received pegﬁlgrastim on day +1.
The IP group received daily ﬁlgrastim starting on day +5.
The OP and IP cohorts were similar in terms of primary
disease (myeloma vs. lymphoma), median age, gender, and
chemo-sensitivity pre-transplant. Karnofsky Performance
Status (KPS) was less favorable in the IP cohort with KPS80
in 36% vs. 6% in the OP cohort (p<.001). There was a trend
toward less favorable Hematopoietic Cell Transplant Co
morbidity Index (HCT-CI) in the IP cohort as well with 53% of
the patients having HCT-CI >/¼3 vs. 40% in the OP cohort
(p¼.060). With regard to transplant characteristics, OP and IP
received a similar CD34 cell dose (4.4 vs. 4.6 x 106/kg,
respectively, p¼.581). Hematopoietic recovery occurred
earlier in the OP cohort, with median time to neutrophil
recovery of 10 vs. 11 days (p<.001) and median time to
platelet recovery of 19 vs. 20 days (p¼.053). For OP AuHCT,
overall 51%were never admitted; for patients transplanted in
2011-2012 this ﬁgure was 61%. For the OP that were
admitted, median length of stay was 9 days. In comparison,
the IP AuHCT patients had a median length of stay of 19 days.
Grade 3-4 non-hematologic toxicities occurred in 29% of both
the OP and IP cohorts. There were no signiﬁcant differences
in speciﬁc adverse events between the two cohorts,
including febrile neutropenia, bacteremia, Clostridium difﬁ-
cile infections, central venous line complications, and
engraftment syndrome. Non-relapse mortality at one year
was 0% in the OP cohort and 1.5% in the IP cohort (p¼.327).
Two year PFS was 62% for OP vs. 54% for IP (p¼.155). One and
two year OS was 97% and 83% for OP vs. 91% and 80% for IP,
respectively (p¼.271).
We conclude that, with careful patient selection and minor
modiﬁcation to the management of neutropenia, OP AuHCT
can result in excellent outcomes for myeloma and lymphoma
patients. OPAuHCT also offers beneﬁt for patients in terms of
enhanced comfort, fewer days in the hospital, and decreased
exposure to sick contacts. Lastly, OP AuHCT is beneﬁcial to
transplant centers due to decreased hospital resource utili-
zation.147
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